Drugs / Recombinant subunit B/bacterial cholera vaccine
Recombinant subunit B/bacterial cholera vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07300462 | Apr 2026 → Jan 2027 expected | diarrheal disease | Shanghai United Cell Biotechnology Co., Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant subunit B/bacterial cholera vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300462 ↗ |
| Modality | Vaccine | “Oral Recombinant Subunit B/Bacterial Cholera Vaccine” NCT07300462 ↗ |
| Route | Oral | “The participants in the experimental group will be given three oral doses of recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)” NCT07300462 ↗ |